In conclusion, this meta-analysis provides strong evidence that SGLT2 inhibitors significantly reduce LFC in adults with metabolic disorders, highlighting their potential role in the management of MASLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.